"#",Jurisdiction,Kind,Display Key,Lens ID,Publication Date,Publication Year,Application Number,Application Date,Priority Numbers,Earliest Priority Date,Title,Abstract,Applicants,Inventors,Owners,URL,Document Type,Has Full Text,Cites Patent Count,Cited by Patent Count,Simple Family Size,Extended Family Size,Sequence Count,CPC Classifications,IPCR Classifications,US Classifications,NPL Citation Count,NPL Resolved Citation Count,NPL Resolved Lens ID(s),NPL Resolved External ID(s),NPL Citations,Legal Status
1,EP,A1,EP 2337517 A1,011-041-243-727-213,2011-06-29,2011,EP 09774456 A,2009-07-01,US 2009/0049427 W;;US 7800408 P,2008-07-03,FLOATING SPINAL CANNULA,,CLEVELAND CLINIC FOUNDATION,BOULIS NICHOLAS M,,https://lens.org/011-041-243-727-213,Patent Application,yes,0,0,8,8,0,A61B5/6848;;A61B17/3401;;A61B17/3478;;A61B2017/00261;;A61B2017/00469;;A61N1/05;;A61B5/407;;A61B2090/3958;;A61B17/3478;;A61N1/05;;A61B2017/00469;;A61B5/6848;;A61B17/3401;;A61B2017/00261;;A61B5/407;;A61B2090/3958,A61B19/00,,0,0,,,,ACTIVE
2,US,A1,US 2005/0019346 A1,129-151-186-066-610,2005-01-27,2005,US 85472604 A,2004-05-27,US 85472604 A;;US 47458103 P,2003-05-30,In vivo production of a clostridial neurotoxin light chain peptide,A method of producing in a cell in vivo a clostridial neurotoxin light chain peptide by delivering into the cell in vivo a nucleic acid construct. The nucleic acid construct comprises (a) a nucleic acid encoding a clostridial neurotoxin light chain peptide and (b) a regulatory sequence operably linked to the nucleic acid to allow expression of the nucleic acid. The expression of the nucleic acid produces the clostridial neurotoxin light chain peptide in the cell in vivo.,BOULIS NICHOLAS M.,BOULIS NICHOLAS M,THE CLEVELAND CLINIC FOUNDATION (2004-05-26),https://lens.org/129-151-186-066-610,Patent Application,yes,5,40,7,7,0,A61K48/005;;A61K48/005;;A61K38/164;;A61K38/164;;C07K14/33;;C07K14/33;;C12N15/86;;C12N15/86;;C12N2710/10343;;C12N2710/10343;;C12N2750/14143;;C12N2750/14143,A61K38/16;;A61K48/00;;C07H21/04;;C07K/;;C07K14/33;;C12N1/21;;C12N15/74;;C12N15/861;;C12N15/864;;C12P21/02,424/190.1;;435/69.3;;435/252.3;;435/320.1;;X53035;;536/23.7,0,0,,,,INACTIVE
3,US,A1,US 2010/0004625 A1,043-388-582-713-434,2010-01-07,2010,US 49640009 A,2009-07-01,US 49640009 A;;US 7800408 P,2008-07-03,FLOATING SPINAL CANNULA AND METHOD OF USE,"A spinal cannula for delivering a therapeutic agent to a spinal cord target includes proximal and distal end portions, a middle portion, and a deployable cannula member having distal and proximal end portions and a first lumen extending between the end portions. The spinal cannula includes a fluid delivery line operably connected to the proximal end portion of the deployable cannula member, and a fluid delivery line including a second lumen in fluid communication with the first lumen. The spinal cannula includes a support cannula proximally located from the deployable cannula member and securely connected to a portion of the fluid delivery line. Additionally, the spinal cannula includes a delivery cannula having distal and proximal end portions and a third lumen extending between the end portions for receiving the support cannula. The proximal end portion includes a locking mechanism for releasably engaging the proximal end portion of the support cannula.",CLEVELAND CLINIC FOUNDATION,BOULIS NICHOLAS M,THE CLEVELAND CLINIC FOUNDATION (2009-07-07),https://lens.org/043-388-582-713-434,Patent Application,yes,3,6,8,8,0,A61B5/6848;;A61B17/3401;;A61B17/3478;;A61B2017/00261;;A61B2017/00469;;A61N1/05;;A61B5/407;;A61B2090/3958;;A61B17/3478;;A61N1/05;;A61B2017/00469;;A61B5/6848;;A61B17/3401;;A61B2017/00261;;A61B5/407;;A61B2090/3958,A61M31/00;;A61M5/178,604/506;;604/164.12,0,0,,,,ACTIVE
4,EP,A4,EP 1631319 A4,120-747-050-103-240,2007-10-31,2007,EP 04753559 A,2004-05-27,US 2004/0016743 W;;US 47458103 P,2003-05-30,IN VIVO PRODUCTION OF A CLOSTRIDIAL NEUROTOXIN LIGHT CHAIN PEPTIDE,,CLEVELAND CLINIC FOUNDATION,BOULIS NICHOLAS M,,https://lens.org/120-747-050-103-240,Search Report,no,2,0,7,7,0,A61K38/164;;A61K48/005;;C07K14/33;;C12N15/86;;C12N2710/10343;;C12N2750/14143;;A61K48/005;;A61K38/164;;C07K14/33;;C12N2750/14143;;C12N2710/10343;;C12N15/86,A61K48/00;;A61K38/16;;C07H21/04;;C07K/;;C07K14/33;;C12N1/21;;C12N15/74;;C12N15/861;;C12N15/864;;C12P21/02,,3,3,008-251-058-584-019;;005-705-908-292-616;;071-483-226-233-443,12376704;;10.1126/science.1074549;;16511525;;10.1038/sj.gt.3302733;;10.1038/sj.gt.3302400;;15496959,"LUO JIA ET AL: ""Subthalamic GAD gene therapy in a Parkinson's disease rat model"", SCIENCE, AMERICAN ASSOCIATION FOR THE ADVANCEMENT OF SCIENCE,, US, vol. 298, no. 5592, 11 October 2002 (2002-10-11), pages 425 - 429, XP002362142, ISSN: 0036-8075;;ZHAO Z ET AL: ""Anatomically discrete functional effects of adenoviral clostridial light chain gene-based synaptic inhibition in the midbrain"", GENE THERAPY, vol. 13, no. 12, June 2006 (2006-06-01), pages 942 - 952, XP002451778, ISSN: 0969-7128;;TENG Q ET AL: ""Adenoviral clostridial light chain gene-based synaptic inhibition through neuronal synaptobrevin elimination"", GENE THERAPY, vol. 12, no. 2, January 2005 (2005-01-01), pages 108 - 119, XP002451779, ISSN: 0969-7128",DISCONTINUED
5,WO,A2,WO 2006/105392 A2,125-262-607-276-699,2006-10-05,2006,US 2006/0011894 W,2006-03-30,US 66647205 P,2005-03-30,NEURON TARGETING PEPTIDES,A neuron targeting peptide includes about 5 to about 30 amino acids and an amino acid sequence that preferentially binds to isolated GT1b,CLEVELAND CLINIC FOUNDATION;;BOULIS NICHOLAS M,BOULIS NICHOLAS M,,https://lens.org/125-262-607-276-699,Patent Application,yes,0,17,2,2,14,C07K7/06;;C07K7/08;;C07K14/475;;G01N33/6845,C07K7/06;;C07K7/08;;C07K14/475;;C07K19/00;;C12N15/864;;G01N33/68,,0,0,,,,PENDING
6,EP,B1,EP 2337517 B1,136-608-404-737-461,2013-01-09,2013,EP 09774456 A,2009-07-01,US 2009/0049427 W;;US 7800408 P,2008-07-03,FLOATING SPINAL CANNULA,,CLEVELAND CLINIC FOUNDATION,BOULIS NICHOLAS M,,https://lens.org/136-608-404-737-461,Granted Patent,yes,3,0,8,8,0,A61B5/6848;;A61B17/3401;;A61B17/3478;;A61B2017/00261;;A61B2017/00469;;A61N1/05;;A61B5/407;;A61B2090/3958;;A61B17/3478;;A61N1/05;;A61B2017/00469;;A61B5/6848;;A61B17/3401;;A61B2017/00261;;A61B5/407;;A61B2090/3958,A61B19/00,,0,0,,,,ACTIVE
7,WO,A1,WO 2010/003006 A1,179-581-886-223-473,2010-01-07,2010,US 2009/0049427 W,2009-07-01,US 7800408 P,2008-07-03,FLOATING SPINAL CANNULA AND METHOD OF USE,"A spinal cannula (10) for delivering a therapeutic agent to a spinal cord target includes proximal and distal end portions, a middle portion, and a deployable cannula member (14) having distal and proximal end portions and a first lumen extending between the end portions. The spinal cannula includes a fluid delivery line (10) operably connected to the proximal end portion of the deployable cannula member, and a fluid delivery line including a second lumen in fluid communication with the first lumen. The spinal cannula includes a support cannula (18) proximally located from the deployable cannula member and securely connected to a portion of the fluid delivery line. Additionally, the spinal cannula includes a delivery cannula (20) having distal and proximal end portions and a third lumen extending between the end portions for receiving the support cannula. The proximal end portion includes a locking mechanism for releasably engaging the proximal end portion of the support cannula.",CLEVELAND CLINIC FOUNDATION,BOULIS NICHOLAS M,,https://lens.org/179-581-886-223-473,Patent Application,yes,6,0,8,8,0,A61B5/6848;;A61B17/3401;;A61B17/3478;;A61B2017/00261;;A61B2017/00469;;A61N1/05;;A61B5/407;;A61B2090/3958;;A61B17/3478;;A61N1/05;;A61B2017/00469;;A61B5/6848;;A61B17/3401;;A61B2017/00261;;A61B5/407;;A61B2090/3958,A61B19/00,,0,0,,,,PENDING
8,WO,A2,WO 2004/111074 A2,181-512-214-509-877,2004-12-23,2004,US 2004/0016743 W,2004-05-27,US 47458103 P,2003-05-30,IN VIVO PRODUCTION OF A CLOSTRIDIAL NEUROTOXIN LIGHT CHAIN PEPTIDE,A method of producing in a cell in vivo a clostridial neurotoxin light chain peptide by delivering into the cell in vivo a nucleic acid construct. The nucleic acid construct comprises (a) a nucleic acid encoding a clostridial neurotoxin light chain peptide and (b) a regulatory sequence operably linked to the nucleic acid to allow expression of the nucleic acid. The expression of the nucleic acid produces the clostridial neurotoxin light chain peptide in the cell in vivo.,CLEVELAND CLINIC FOUNDATION,BOULIS NICHOLAS M,,https://lens.org/181-512-214-509-877,Patent Application,yes,0,3,7,7,0,A61K48/005;;A61K48/005;;A61K38/164;;A61K38/164;;C07K14/33;;C07K14/33;;C12N15/86;;C12N15/86;;C12N2710/10343;;C12N2710/10343;;C12N2750/14143;;C12N2750/14143,A61K38/16;;A61K48/00;;C07H21/04;;C07K/;;C07K14/33;;C12N1/21;;C12N15/74;;C12N15/861;;C12N15/864;;C12P21/02,,1,0,,,See references of EP 1631319A4,PENDING
9,WO,A4,WO 2010/003006 A4,052-654-601-641-68X,2010-03-25,2010,US 2009/0049427 W,2009-07-01,US 7800408 P,2008-07-03,FLOATING SPINAL CANNULA AND METHOD OF USE,"A spinal cannula (10) for delivering a therapeutic agent to a spinal cord target includes proximal and distal end portions, a middle portion, and a deployable cannula member (14) having distal and proximal end portions and a first lumen extending between the end portions. The spinal cannula includes a fluid delivery line (10) operably connected to the proximal end portion of the deployable cannula member, and a fluid delivery line including a second lumen in fluid communication with the first lumen. The spinal cannula includes a support cannula (18) proximally located from the deployable cannula member and securely connected to a portion of the fluid delivery line. Additionally, the spinal cannula includes a delivery cannula (20) having distal and proximal end portions and a third lumen extending between the end portions for receiving the support cannula. The proximal end portion includes a locking mechanism for releasably engaging the proximal end portion of the support cannula.",CLEVELAND CLINIC FOUNDATION,BOULIS NICHOLAS M,,https://lens.org/052-654-601-641-68X,Patent Application,yes,0,0,8,8,0,A61B5/6848;;A61B17/3401;;A61B17/3478;;A61B2017/00261;;A61B2017/00469;;A61N1/05;;A61B5/407;;A61B2090/3958;;A61B17/3478;;A61N1/05;;A61B2017/00469;;A61B5/6848;;A61B17/3401;;A61B2017/00261;;A61B5/407;;A61B2090/3958,A61B19/00,,0,0,,,,PENDING
10,WO,A9,WO 2004/111074 A9,187-350-871-777-993,2005-03-24,2005,US 2004/0016743 W,2004-05-27,US 47458103 P,2003-05-30,IN VIVO PRODUCTION OF A CLOSTRIDIAL NEUROTOXIN LIGHT CHAIN PEPTIDE,A method of producing in a cell in vivo a clostridial neurotoxin light chain peptide by delivering into the cell in vivo a nucleic acid construct. The nucleic acid construct comprises (a) a nucleic acid encoding a clostridial neurotoxin light chain peptide and (b) a regulatory sequence operably linked to the nucleic acid to allow expression of the nucleic acid. The expression of the nucleic acid produces the clostridial neurotoxin light chain peptide in the cell in vivo.,CLEVELAND CLINIC FOUNDATION,BOULIS NICHOLAS M,,https://lens.org/187-350-871-777-993,Patent Application,no,0,0,7,7,0,A61K48/005;;A61K48/005;;A61K38/164;;A61K38/164;;C07K14/33;;C07K14/33;;C12N15/86;;C12N15/86;;C12N2710/10343;;C12N2710/10343;;C12N2750/14143;;C12N2750/14143,A61K38/16;;A61K48/00;;C07H21/04;;C07K/;;C07K14/33;;C12N1/21;;C12N15/74;;C12N15/861;;C12N15/864;;C12P21/02,,0,0,,,,PENDING
11,US,B2,US 8708962 B2,099-209-156-783-128,2014-04-29,2014,US 91352710 A,2010-10-27,US 91352710 A;;US 49640009 A;;US 7800408 P,2008-07-03,Floating spinal cannula and method of use,"A spinal cannula for delivering a therapeutic agent to a spinal cord target includes proximal and distal end portions, a middle portion, and a deployable cannula member having distal and proximal end portions and a first lumen extending between the end portions. The spinal cannula includes a fluid delivery line operably connected to the proximal end portion of the deployable cannula member, and a fluid delivery line including a second lumen in fluid communication with the first lumen. The spinal cannula includes a support cannula proximally located from the deployable cannula member and securely connected to a portion of the fluid delivery line. Additionally, the spinal cannula includes a delivery cannula having distal and proximal end portions and a third lumen extending between the end portions for receiving the support cannula. The proximal end portion includes a locking mechanism for releasably engaging the proximal end portion of the support cannula.",BOULIS NICHOLAS M;;CLEVELAND CLINIC FOUNDATION,BOULIS NICHOLAS M,,https://lens.org/099-209-156-783-128,Granted Patent,yes,10,0,8,8,0,A61B5/6848;;A61B17/3401;;A61B17/3478;;A61B2017/00261;;A61B2017/00469;;A61N1/05;;A61B5/407;;A61B2090/3958;;A61B17/3478;;A61N1/05;;A61B2017/00469;;A61B5/6848;;A61B17/3401;;A61B2017/00261;;A61B5/407;;A61B2090/3958,A61M5/178,604/164.01;;604/533,0,0,,,,ACTIVE
12,US,A1,US 2011/0046554 A1,177-422-103-693-700,2011-02-24,2011,US 91352710 A,2010-10-27,US 91352710 A;;US 49640009 A;;US 7800408 P,2008-07-03,FLOATING SPINAL CANNULA AND METHOD OF USE,"A spinal cannula for delivering a therapeutic agent to a spinal cord target includes proximal and distal end portions, a middle portion, and a deployable cannula member having distal and proximal end portions and a first lumen extending between the end portions. The spinal cannula includes a fluid delivery line operably connected to the proximal end portion of the deployable cannula member, and a fluid delivery line including a second lumen in fluid communication with the first lumen. The spinal cannula includes a support cannula proximally located from the deployable cannula member and securely connected to a portion of the fluid delivery line. Additionally, the spinal cannula includes a delivery cannula having distal and proximal end portions and a third lumen extending between the end portions for receiving the support cannula. The proximal end portion includes a locking mechanism for releasably engaging the proximal end portion of the support cannula.",BOULIS NICHOLAS M,BOULIS NICHOLAS M,,https://lens.org/177-422-103-693-700,Patent Application,yes,8,0,8,8,0,A61B5/6848;;A61B17/3401;;A61B17/3478;;A61B2017/00261;;A61B2017/00469;;A61N1/05;;A61B5/407;;A61B2090/3958;;A61B17/3478;;A61N1/05;;A61B2017/00469;;A61B5/6848;;A61B17/3401;;A61B2017/00261;;A61B5/407;;A61B2090/3958,A61M5/178,604/164.01,0,0,,,,ACTIVE
13,WO,A3,WO 2006/105392 A3,002-261-287-241-90X,2007-04-05,2007,US 2006/0011894 W,2006-03-30,US 66647205 P,2005-03-30,NEURON TARGETING PEPTIDES,A neuron targeting peptide includes about 5 to about 30 amino acids and an amino acid sequence that preferentially binds to isolated G T1b,CLEVELAND CLINIC FOUNDATION;;BOULIS NICHOLAS M,BOULIS NICHOLAS M,,https://lens.org/002-261-287-241-90X,Search Report,yes,2,0,2,2,14,C07K7/06;;C07K7/08;;C07K14/475;;G01N33/6845,C07K7/06;;C07K7/08;;C07K14/475;;C07K19/00;;C12N15/864;;G01N33/68,,1,1,012-952-547-397-501,16023583;;10.1016/j.nbd.2005.01.022,"LIU J K ET AL: ""A novel peptide defined through phage display for therapeutic protein and vector neuronal targeting"", NEUROBIOLOGY OF DISEASE, BLACKWELL SCIENCE, OXFORD, GB, vol. 19, no. 3, 18 March 2005 (2005-03-18), pages 407 - 418, XP004977684, ISSN: 0969-9961",PENDING
14,WO,A3,WO 2004/111074 A3,094-539-952-300-14X,2005-12-22,2005,US 2004/0016743 W,2004-05-27,US 47458103 P,2003-05-30,IN VIVO PRODUCTION OF A CLOSTRIDIAL NEUROTOXIN LIGHT CHAIN PEPTIDE,A method of producing in a cell in vivo a clostridial neurotoxin light chain peptide by delivering into the cell in vivo a nucleic acid construct. The nucleic acid construct comprises (a) a nucleic acid encoding a clostridial neurotoxin light chain peptide and (b) a regulatory sequence operably linked to the nucleic acid to allow expression of the nucleic acid. The expression of the nucleic acid produces the clostridial neurotoxin light chain peptide in the cell in vivo.,CLEVELAND CLINIC FOUNDATION,BOULIS NICHOLAS M,,https://lens.org/094-539-952-300-14X,Search Report,yes,4,0,7,7,0,A61K48/005;;A61K48/005;;A61K38/164;;A61K38/164;;C07K14/33;;C07K14/33;;C12N15/86;;C12N15/86;;C12N2710/10343;;C12N2710/10343;;C12N2750/14143;;C12N2750/14143,A61K38/16;;A61K48/00;;C07H21/04;;C07K/;;C07K14/33;;C12N1/21;;C12N15/74;;C12N15/861;;C12N15/864;;C12P21/02,,1,0,,,See also references of EP 1631319A4,PENDING
15,US,B2,US 7704685 B2,037-806-016-810-143,2010-04-27,2010,US 85472604 A,2004-05-27,US 85472604 A;;US 47458103 P,2003-05-30,In vivo production of a clostridial neurotoxin light chain peptide,A method of producing in a cell in vivo a clostridial neurotoxin light chain peptide by delivering into the cell in vivo a nucleic acid construct. The nucleic acid construct comprises (a) a nucleic acid encoding a clostridial neurotoxin light chain peptide and (b) a regulatory sequence operably linked to the nucleic acid to allow expression of the nucleic acid. The expression of the nucleic acid produces the clostridial neurotoxin light chain peptide in the cell in vivo.,CLEVELAND CLINIC FOUNDATION,BOULIS NICHOLAS M,THE CLEVELAND CLINIC FOUNDATION (2004-05-26),https://lens.org/037-806-016-810-143,Granted Patent,yes,5,0,7,7,0,A61K48/005;;A61K48/005;;A61K38/164;;A61K38/164;;C07K14/33;;C07K14/33;;C12N15/86;;C12N15/86;;C12N2710/10343;;C12N2710/10343;;C12N2750/14143;;C12N2750/14143,C12Q1/00;;A61K38/16;;A61K48/00;;C07H21/02;;C07H21/04;;C07K/;;C07K14/33;;C12N1/21;;C12N15/74;;C12N15/861;;C12N15/864;;C12P21/02,435/4;;536/23.7;;536/23.1,1,1,036-097-914-291-933,12450285;;10.3171/spi.2002.96.2.0212,"Boulis, N.M., et al. ""Neuronal survival following remote adenovirus gene delivery"", Journal of Neurosurgery, vol. 96, pp. 212-219, 2002.",INACTIVE
16,US,B2,US 7833217 B2,079-817-644-923-883,2010-11-16,2010,US 49640009 A,2009-07-01,US 49640009 A;;US 7800408 P,2008-07-03,Floating spinal cannula and method of use,"A spinal cannula for delivering a therapeutic agent to a spinal cord target includes proximal and distal end portions, a middle portion, and a deployable cannula member having distal and proximal end portions and a first lumen extending between the end portions. The spinal cannula includes a fluid delivery line operably connected to the proximal end portion of the deployable cannula member, and a fluid delivery line including a second lumen in fluid communication with the first lumen. The spinal cannula includes a support cannula proximally located from the deployable cannula member and securely connected to a portion of the fluid delivery line. Additionally, the spinal cannula includes a delivery cannula having distal and proximal end portions and a third lumen extending between the end portions for receiving the support cannula. The proximal end portion includes a locking mechanism for releasably engaging the proximal end portion of the support cannula.",CLEVELAND CLINIC FOUNDATION,BOULIS NICHOLAS M,THE CLEVELAND CLINIC FOUNDATION (2009-07-07),https://lens.org/079-817-644-923-883,Granted Patent,yes,10,6,8,8,0,A61B5/6848;;A61B17/3401;;A61B17/3478;;A61B2017/00261;;A61B2017/00469;;A61N1/05;;A61B5/407;;A61B2090/3958;;A61B17/3478;;A61N1/05;;A61B2017/00469;;A61B5/6848;;A61B17/3401;;A61B2017/00261;;A61B5/407;;A61B2090/3958,A61M25/00,604/523;;604/240;;604/533,0,0,,,,ACTIVE
17,EP,A2,EP 1631319 A2,170-006-080-565-302,2006-03-08,2006,EP 04753559 A,2004-05-27,US 2004/0016743 W;;US 47458103 P,2003-05-30,IN VIVO PRODUCTION OF A CLOSTRIDIAL NEUROTOXIN LIGHT CHAIN PEPTIDE,,CLEVELAND CLINIC FOUNDATION,BOULIS NICHOLAS M,,https://lens.org/170-006-080-565-302,Patent Application,yes,0,0,7,7,0,A61K48/005;;A61K48/005;;A61K38/164;;A61K38/164;;C07K14/33;;C07K14/33;;C12N15/86;;C12N15/86;;C12N2710/10343;;C12N2710/10343;;C12N2750/14143;;C12N2750/14143,A61K38/16;;A61K48/00;;C07H21/04;;C07K/;;C07K14/33;;C12N1/21;;C12N15/74;;C12N15/861;;C12N15/864;;C12P21/02,,0,0,,,,DISCONTINUED
18,IL,A,IL 300254 A,151-892-739-609-917,2023-03-01,2023,IL 30025423 A,2023-01-29,US 201662292157 P;;US 2017/0014914 W,2016-02-05,Administration of single stranded or self-complementary adeno-associated virus 9 by injection into the cerebrospinal fluid to target gene therapy to the central nervous system,,UNIV EMORY;;REGENXBIO INC;;NICHOLAS MATTHEW BOULIS;;JONATHAN PATRICK RILEY,NICHOLAS MATTHEW BOULIS;;JONATHAN PATRICK RILEY,,https://lens.org/151-892-739-609-917,Patent Application,no,0,0,22,22,0,C12N15/86;;C12N2750/14143;;A61K48/0075;;A61P37/00;;A61P25/00;;A61K48/0075;;A61P25/00;;A61K9/0085;;C12N2750/14143;;C12N15/86;;C12N2750/14143;;C12N15/86;;A61K48/0075;;A61P37/00;;A61P25/00;;A61K9/0085;;A61K45/06,A61K45/06;;A61K48/00;;A61P25/00;;A61P37/00;;C12N15/86,,0,0,,,,PENDING
19,IL,B1,IL 260954 B1,192-078-258-892-660,2023-03-01,2023,IL 26095418 A,2018-08-02,US 201662292157 P;;US 2017/0014914 W,2016-02-05,Administration of single stranded or self-complementary adeno-associated virus 9 by injection into the cerebrospinal fluid to target gene therapy to the central nervous system,,UNIV EMORY;;REGENXBIO INC;;NICHOLAS MATTHEW BOULIS;;JONATHAN PATRICK RILEY,NICHOLAS MATTHEW BOULIS;;JONATHAN PATRICK RILEY,,https://lens.org/192-078-258-892-660,Unknown,no,2,0,22,22,0,C12N15/86;;C12N2750/14143;;A61K48/0075;;A61P37/00;;A61P25/00;;A61K48/0075;;A61P25/00;;A61K9/0085;;C12N2750/14143;;C12N15/86;;C12N2750/14143;;C12N15/86;;A61K48/0075;;A61P37/00;;A61P25/00;;A61K9/0085;;A61K45/06,A61K48/00;;A61P25/00;;C12N15/86,,1,1,017-883-197-052-137,25358252;;10.1038/mt.2014.210;;pmc4351452,"MEYER, KATHRIN, ET AL., IMPROVING SINGLE INJECTION CSF DELIVERY OF AAV9-MEDIATED GENE THERAPY FOR SMA: A DOSE–RESPONSE STUDY IN MICE AND NONHUMAN PRIMATES., 9 December 2014 (2014-12-09)",PENDING
20,IL,B2,IL 260954 B2,193-120-524-872-391,2023-07-01,2023,IL 26095418 A,2018-08-02,US 201662292157 P;;US 2017/0014914 W,2016-02-05,Administration of single stranded or self-complementary adeno-associated virus 9 by injection into the cerebrospinal fluid to target gene therapy to the central nervous system,,UNIV EMORY;;REGENXBIO INC;;NICHOLAS MATTHEW BOULIS;;JONATHAN PATRICK RILEY,NICHOLAS MATTHEW BOULIS;;JONATHAN PATRICK RILEY,,https://lens.org/193-120-524-872-391,Unknown,no,2,0,22,22,0,C12N15/86;;C12N2750/14143;;A61K48/0075;;A61P37/00;;A61P25/00;;A61K48/0075;;A61P25/00;;A61K9/0085;;C12N2750/14143;;C12N15/86;;C12N2750/14143;;C12N15/86;;A61K48/0075;;A61P37/00;;A61P25/00;;A61K9/0085;;A61K45/06,A61K48/00;;A61P25/00;;C12N15/86,,1,1,017-883-197-052-137,25358252;;10.1038/mt.2014.210;;pmc4351452,"MEYER, KATHRIN, ET AL., IMPROVING SINGLE INJECTION CSF DELIVERY OF AAV9-MEDIATED GENE THERAPY FOR SMA: A DOSE–RESPONSE STUDY IN MICE AND NONHUMAN PRIMATES., 9 December 2014 (2014-12-09)",PENDING
21,US,B2,US 8092495 B2,028-615-444-814-281,2012-01-10,2012,US 41817009 A,2009-04-03,US 41817009 A;;US 4230708 P;;US 8278708 P,2008-04-04,Spinal platform and method for delivering a therapeutic agent to a spinal cord target,"A spinal platform for delivering a therapeutic agent to a spinal cord target includes a brace member for attachment to a plurality of bony structures surrounding at least a portion of the spinal cord target, a carriage member operatively coupled to and movable along the brace member, and a universal joint for adjusting the coronal or sagittal angle of a surgical instrument. The brace member includes at least one longitudinal rail and a plurality of attachment members. The plurality of attachment members is operably connected to the at least one longitudinal rail. The at least one longitudinal rail includes a proximal end portion, a distal end portion, and a middle portion extending between the proximal and distal end portions. The universal joint is seated within a portion of the carriage member and is capable of delivering the therapeutic agent to the spinal cord target.",BOULIS NICHOLAS M;;SHAWAN ANTHONY J;;KOTSCHI HELMUTH;;CLEVELAND CLINIC FOUNDATION,BOULIS NICHOLAS M;;SHAWAN ANTHONY J;;KOTSCHI HELMUTH,THE CLEVELAND CLINIC FOUNDATION (2008-11-13),https://lens.org/028-615-444-814-281,Granted Patent,yes,7,14,5,5,0,A61B17/0206;;A61B17/0206;;A61B17/3403;;A61B17/3403;;A61B17/3472;;A61B17/3472;;A61B90/11;;A61B90/11;;A61B90/14;;A61B90/14;;A61B90/50;;A61B90/50;;A61B2017/3407;;A61B2017/3407;;A61B2090/067;;A61B2090/067;;A61M2210/1003;;A61M2210/1003,A61B17/70,606/246;;604/116;;604/512;;606/92,2,1,040-102-764-277-164,18073518;;10.1159/000112426,"Riley et al., ""Cervical Spinal Cord Therapeutics Delivery: Preclinical Safety Validation of a Tabilized Microinjection Platform"", Neurosurgery, reprinted from www.neurosurgery-online.com on Mar. 30, 2009, pp. 1-8.;;Riley et al., ""Targeted Spinal Cord Therapeutics Delivery: Stabilized Platform and Microelectrode Recording Guidance Validation"", Stereotact Funct Neurosurg 151, Aug. 11, 2007, pp. 1-8.",ACTIVE
22,US,A1,US 2010/0030184 A1,148-961-498-347-837,2010-02-04,2010,US 41817009 A,2009-04-03,US 41817009 A;;US 4230708 P;;US 8278708 P,2008-04-04,SPINAL PLATFORM AND METHOD FOR DELIVERING A THERAPEUTIC AGENT TO A SPINAL CORD TARGET,"A spinal platform for delivering a therapeutic agent to a spinal cord target includes a brace member for attachment to a plurality of bony structures surrounding at least a portion of the spinal cord target, a carriage member operatively coupled to and movable along the brace member, and a universal joint for adjusting the coronal or sagittal angle of a surgical instrument. The brace member includes at least one longitudinal rail and a plurality of attachment members. The plurality of attachment members is operably connected to the at least one longitudinal rail. The at least one longitudinal rail includes a proximal end portion, a distal end portion, and a middle portion extending between the proximal and distal end portions. The universal joint is seated within a portion of the carriage member and is capable of delivering the therapeutic agent to the spinal cord target.",CLEVELAND CLINIC FOUNDATION,BOULIS NICHOLAS M;;SHAWAN ANTHONY J;;KOTSCHI HELMUTH,THE CLEVELAND CLINIC FOUNDATION (2008-11-13),https://lens.org/148-961-498-347-837,Patent Application,yes,6,32,5,5,0,A61B17/0206;;A61B17/0206;;A61B17/3403;;A61B17/3403;;A61B17/3472;;A61B17/3472;;A61B90/11;;A61B90/11;;A61B90/14;;A61B90/14;;A61B90/50;;A61B90/50;;A61B2017/3407;;A61B2017/3407;;A61B2090/067;;A61B2090/067;;A61M2210/1003;;A61M2210/1003,A61M31/00;;A61B17/00,604/500;;604/48;;606/53,0,0,,,,ACTIVE
23,US,A1,US 2017/0079864 A1,170-273-984-864-360,2017-03-23,2017,US 201615273349 A,2016-09-22,US 201615273349 A;;US 201562221662 P,2015-09-22,Surgical Support Devices and Systems,"These systems and devices can be placed on top of any commercially available standard operating table and therefore can provide a portable and inexpensive alternative to commercially available specialized operating tables. The system may include a frame body having a first end, a second end, and a length therebetween. The system may also include one or more movable platforms having a first end, a second end, and a length therebetween. Each moveable platform may be configured to move between the first end and the second end of the frame body. The system may also include one or more stabilizing support members disposed parallel to the first end and the second end of the frame body and configured to move along the length of the movable platform. Each stabilizing support member may include one or more securing members configured for removable, active and/or removable fixation with respect to the movable platform.",UNIV EMORY,RILEY JONATHAN;;BOULIS NICHOLAS;;RAJU SUKREET;;MCDONOUGH ANNIE,,https://lens.org/170-273-984-864-360,Patent Application,yes,0,29,1,1,0,A61G13/1285;;A61G13/1295;;A61G13/122;;A61G13/122;;A61G13/123;;A61G13/123;;A61G13/1245;;A61G13/1245;;A61G13/129;;A61G2200/325;;A61G2200/325;;A61G2210/50;;A61G2210/50,A61G13/12,,0,0,,,,DISCONTINUED
24,US,A1,US 2019/0030007 A1,086-183-556-140-207,2019-01-31,2019,US 201715664937 A,2017-07-31,US 201715664937 A,2017-07-31,FORMULATION OF A RILUZOLE SOLUTION WITH BETA-CYCLODEXTRINS,The present invention provides methods for parenterally administering riluzole to subjects in need of treatment.,ABOVE AND BEYOND NB LLC;;UNIV EMORY,BETOURNE ALEXANDRE;;BOULIS NICHOLAS M;;BARTUS RAYMOND T,EMORY UNIVERSITY (2017-10-19);;ABOVE AND BEYOND NB LLC (2017-10-24),https://lens.org/086-183-556-140-207,Patent Application,yes,0,0,4,4,0,A61K31/428;;A61K9/0085;;A61K9/08;;A61K47/40;;A61K31/428;;A61K9/0085;;A61K9/0053;;A61K9/08;;A61K47/40;;A61K9/0019,A61K31/428;;A61K9/00;;A61K9/08;;A61K47/40,,0,0,,,,ACTIVE
25,US,B2,US 10322114 B2,149-531-839-063-039,2019-06-18,2019,US 201715664937 A,2017-07-31,US 201715664937 A,2017-07-31,Formulation of a riluzole solution with beta-cyclodextrins,The present invention provides methods for parenterally administering riluzole to subjects in need of treatment.,ABOVE AND BEYOND NB LLC;;UNIV EMORY,BETOURNE ALEXANDRE;;BOULIS NICHOLAS M;;BARTUS RAYMOND T,EMORY UNIVERSITY (2017-10-19);;ABOVE AND BEYOND NB LLC (2017-10-24),https://lens.org/149-531-839-063-039,Granted Patent,yes,5,1,4,4,0,A61K31/428;;A61K9/0085;;A61K9/08;;A61K47/40;;A61K31/428;;A61K9/0085;;A61K9/0053;;A61K9/08;;A61K47/40;;A61K9/0019,A61K31/428;;A61K9/00;;A61K9/08;;A61K47/40,,5,3,038-264-917-900-245;;093-063-581-227-117;;049-288-330-004-21X,18721116;;10.1517/17425255.4.9.1223;;pmc2587133;;pmc3675066;;23762454;;10.1371/journal.pone.0065976;;10.1227/01.neu.0000489810.52605.80;;27399519,"Carlos Zarate (Expert Opin Drug Metab Toxicol. Sep. 2008 ; 4(9): 1223-1234) (Year: 2008).;;Li J, Sung M, Rutkove SB (2013) Electrophysiologic Biomarkers for Assessing Disease Progression and the Effect of Riluzole in SOD1 G93A ALS Mice. PLoS ONE 8(6): (Year: 2013).;;Detailed pharmacology review of neuroprotective agents for ALS Traynor BJ et al. 2005 (Year: 2005).;;Guiterrez et al., “Development of Intrathecal Riluzole: A New Route of Administration for the Treatment of Amyotrophic Lateral Sclerosis Patients,” Neurosurgery, 2016, pp. 193, vol. 63.;;Wang et al, “Characterization and evaluation of synthetic riluzole with β-cyclodextrin and 2,6-di-O-methyl-β-cyclodextrin inclusion complexes,” Carbohydrate Polymers, 2015, pp. 9-16, vol. 129.",ACTIVE
26,EP,A1,EP 2274041 A1,106-103-617-246-875,2011-01-19,2011,EP 09728142 A,2009-04-03,US 2009/0039451 W;;US 4230708 P;;US 8278708 P,2008-04-04,SPINAL PLATFORM FOR DELIVERING A THERAPEUTIC AGENT TO A SPINAL CORD TARGET,,CLEVELAND CLINIC FOUNDATION,BOULIS NICHOLAS M;;SHAWAN ANTHONY J;;KOTSCHI HELMUTH,,https://lens.org/106-103-617-246-875,Patent Application,yes,0,0,5,5,0,A61B17/0206;;A61B17/0206;;A61B17/3403;;A61B17/3403;;A61B17/3472;;A61B17/3472;;A61B90/11;;A61B90/11;;A61B90/14;;A61B90/14;;A61B90/50;;A61B90/50;;A61B2017/3407;;A61B2017/3407;;A61B2090/067;;A61B2090/067;;A61M2210/1003;;A61M2210/1003,A61M37/00;;A61B90/00;;A61B90/14;;A61B90/50,,1,0,,,See references of WO 2009124244A1,ACTIVE
27,US,A1,US 2021/0008038 A1,154-721-842-359-082,2021-01-14,2021,US 202016790035 A,2020-02-13,US 202016790035 A;;US 201916352499 A;;US 201715664937 A,2017-07-31,FORMULATION OF A RILUZOLE SOLUTION WITH BETA-CYCLODEXTRINS,The present invention provides methods for parenterally administering riluzole to subjects in need of treatment.,ABOVE AND BEYOND NB LLC;;UNIV EMORY,BETOURNE ALEXANDRE;;BOULIS NICHOLAS M;;BARTUS RAYMOND T,EMORY UNIVERSITY (2017-10-19);;ABOVE AND BEYOND NB LLC (2017-10-24),https://lens.org/154-721-842-359-082,Patent Application,yes,4,0,4,4,0,A61K31/428;;A61K9/0085;;A61K9/08;;A61K47/40;;A61K31/428;;A61K9/0085;;A61K9/0053;;A61K9/08;;A61K47/40;;A61K9/0019,A61K31/428;;A61K9/00;;A61K9/08;;A61K47/40,,8,2,052-986-567-100-396;;074-737-893-283-141,15041570;;10.1213/01.ane.0000105878.96434.05;;10.1097/aap.0000000000000107;;24956455;;pmc4218763,"Groban et al., Intrathecal morphine reduces infarct size in a rat model of ischemia-reperfusion injury. Anesth Analg. 2004 Apr;98(4):903-909, printed from https://pubmed.ncbi.nlm.nih.gov/15041570/, 1 page, abstract only;;Winfield, Pharmaceutical Practice, Parenteral Products-Buffers, Churchill Livingstone, 2004, 255;;Wang et al., Characterization and evaluation of synthetic riluzole with β-cyclodextrin and 2,6-di-O-methyl-β-cyclodextrin inclusion complexes. Carbohydr Polym. 2015 Sep 20;129:9-16, Epub 2015 Apr 30, printed from https://pubmed.ncbi.nlm.nih.gov/26050882/, 1 page, Abstract only;;Antranik.org, Parenteral Administration (Injectable), 4/21/2016, printed from https://web.archive.org/web/20160421114211/https://antranik.org/parenteral-administration-injectable/, 4 pages;;Wang et al., The influence of hydroxypropyl-β-cyclodextrin on the solubility, dissolution, cytotoxicity, and binding of riluzole with human serum albumin, J Pharm Biomed Anal. 2016 Jan 5;117:453-63. Epub 2015 Oct 9., printed from https://pubmed.ncbi.nlm.nih.gov/26454338/, Abstract only, 2 pages;;Wesemann et al., Clinical accuracy and safety using the SynchroMed II intrathecal drug infusion pump, Reg Anesth Pain Med. 2014 Jul-Aug;39(4):341-6. printed from https://pubmed.ncbi.nlm.nih.gov/24956455/, Abstract only, 2 pages;;Medtronic, Synchromed II-Implant manual, 9-2011, printed from http://www.neuromodulation.ch/sites/default/files/pictures/synchromed_II_implant_manuel.pdf, 26 pages;;ALS worldwide, (Rilutek (riluzole), 2/2/2015, printed from https://alsworldwide.org/research-and-trials/article/rilutek-riluzole, 3 pages",PENDING
28,WO,A1,WO 2009/124244 A1,158-263-662-457-048,2009-10-08,2009,US 2009/0039451 W,2009-04-03,US 4230708 P;;US 8278708 P,2008-04-04,SPINAL PLATFORM AND METHOD FOR DELIVERING A THERAPEUTIC AGENT TO A SPINAL CORD TARGET,"A spinal platform for delivering a therapeutic agent to a spinal cord target includes a brace member for attachment to a plurality of bony structures surrounding at least a portion of the spinal cord target, a carriage member operatively coupled to and movable along the brace member, and a universal joint for adjusting the coronal or sagittal angle of a surgical instrument. The brace member includes at least one longitudinal rail and a plurality of attachment members. The plurality of attachment members is operably connected to the at least one longitudinal rail. The at least one longitudinal rail includes a proximal end portion, a distal end portion, and a middle portion extending between the proximal and distal end portions. The universal joint is seated within a portion of the carriage member and is capable of delivering the therapeutic agent to the spinal cord target.",CLEVELAND CLINIC FOUNDATION,BOULIS NICHOLAS M;;SHAWAN ANTHONY J;;KOTSCHI HELMUTH,,https://lens.org/158-263-662-457-048,Patent Application,yes,3,9,5,5,0,A61B17/0206;;A61B17/0206;;A61B17/3403;;A61B17/3403;;A61B17/3472;;A61B17/3472;;A61B90/11;;A61B90/11;;A61B90/14;;A61B90/14;;A61B90/50;;A61B90/50;;A61B2017/3407;;A61B2017/3407;;A61B2090/067;;A61B2090/067;;A61M2210/1003;;A61M2210/1003,A61M37/00;;A61B19/00,,0,0,,,,PENDING
29,EP,B1,EP 2274041 B1,032-905-984-534-109,2016-06-08,2016,EP 09728142 A,2009-04-03,US 2009/0039451 W;;US 4230708 P;;US 8278708 P,2008-04-04,SPINAL PLATFORM FOR DELIVERING A THERAPEUTIC AGENT TO A SPINAL CORD TARGET,,CLEVELAND CLINIC FOUNDATION,BOULIS NICHOLAS M;;SHAWAN ANTHONY J;;KOTSCHI HELMUTH,,https://lens.org/032-905-984-534-109,Granted Patent,yes,3,0,5,5,0,A61B17/0206;;A61B17/0206;;A61B17/3403;;A61B17/3403;;A61B17/3472;;A61B17/3472;;A61B90/11;;A61B90/11;;A61B90/14;;A61B90/14;;A61B90/50;;A61B90/50;;A61B2017/3407;;A61B2017/3407;;A61B2090/067;;A61B2090/067;;A61M2210/1003;;A61M2210/1003,A61M37/00;;A61B90/00;;A61B90/14;;A61B90/50,,0,0,,,,ACTIVE
30,US,A1,US 2019/0269660 A1,192-091-441-871-16X,2019-09-05,2019,US 201916352499 A,2019-03-13,US 201916352499 A;;US 201715664937 A,2017-07-31,FORMULATION OF A RILUZOLE SOLUTION WITH BETA- CYCLODEXTRINS,The present invention provides methods for parenterally administering riluzole to subjects in need of treatment.,ABOVE AND BEYOND NB LLC;;UNIV EMORY,BETOURNE ALEXANDRE;;BOULIS NICHOLAS M;;BARTUS RAYMOND T,,https://lens.org/192-091-441-871-16X,Patent Application,yes,0,0,4,4,0,A61K31/428;;A61K9/0085;;A61K9/08;;A61K47/40;;A61K31/428;;A61K9/0085;;A61K9/0053;;A61K9/08;;A61K47/40;;A61K9/0019,A61K31/428;;A61K9/00;;A61K9/08;;A61K47/40,,2,2,093-063-581-227-117;;038-264-917-900-245,pmc3675066;;23762454;;10.1371/journal.pone.0065976;;18721116;;10.1517/17425255.4.9.1223;;pmc2587133,"Li J, Sung M, Rutkove SB (2013) Electrophysiologic Biomarkers for Assessing Disease Progression and the Effect of Riluzole in SOD1 G93A ALS Mice. PLoSONE 8(6) (Year: 2013);;Zarate et al Expert Opin Drug Metab Toxicol. 2008 Sep; 4(9): 1223–1234. (Year: 2008)",DISCONTINUED
31,EP,A2,EP 4299079 A2,051-351-002-075-001,2024-01-03,2024,EP 23194145 A,2017-01-25,US 201662292157 P;;EP 17747935 A;;US 2017/0014914 W,2016-02-05,INJECTION OF SINGLE-STRANDED OR SELF-COMPLEMENTARY ADENO-ASSOCIATED VIRUS 9 INTO THE CEREBROSPINAL FLUID,"It is disclosed herein that ssAAV and scAAV vectors of the same serotype administered by injection into the cerebrospinal fluid (CSF) via the intracerebroventricular (ICV) or intrathecal (cisternal or lumbar) route exhibit different cellular tropisms in the central nervous system. Thus, a subject can be treated by injection into the CSF of ssAAV or scAAV vector encoding a therapeutic protein, such as an ssAAV9 or scAAV9 vector. The therapeutic protein can be targeted to specific cells using these vectors. In some embodiments, scAAV9 is utilized to achieve superior transduction in the hippocampus, cerebellum and cerebral cortex where both neurons, particularly Purkinje neurons, and glial cells (such as astrocytes) are transduced. In other embodiments, ssAAV9 is utilized to minimize transduction of astrocytes. In further embodiments, an immunosuppressive agent is also administered to the subject.
",UNIV EMORY;;REGENXBIO INC,DONSANTE ANTHONY;;KOZARSKY KAREN;;BOULIS NICHOLAS MATTHEW;;RILEY JONATHAN PATRICK,,https://lens.org/051-351-002-075-001,Patent Application,yes,18,0,22,22,0,C12N15/86;;C12N2750/14143;;A61K48/0075;;A61P37/00;;A61P25/00;;A61K48/0075;;A61P25/00;;A61K9/0085;;C12N2750/14143;;C12N15/86;;C12N2750/14143;;C12N15/86;;A61K48/0075;;A61P37/00;;A61P25/00;;A61K9/0085;;A61K45/06,A61K48/00,,94,76,028-176-723-258-749;;003-940-906-194-446;;062-055-042-396-670;;097-421-754-978-369;;060-628-737-164-756;;014-447-506-623-31X;;014-270-217-613-579;;007-270-294-063-175;;043-098-399-842-988;;042-145-179-004-555;;049-358-720-480-087;;074-552-807-066-167;;057-397-521-955-782;;023-595-385-560-64X;;032-728-154-591-070;;085-764-009-624-439;;104-132-094-161-775;;038-383-743-124-048;;066-141-497-990-023;;056-201-471-905-934;;028-862-168-091-90X;;023-907-179-348-058;;010-884-480-301-434;;016-617-627-772-41X;;043-271-014-136-772;;049-645-318-851-478;;010-787-697-332-659;;020-134-111-407-516;;038-993-273-741-436;;088-927-854-299-269;;074-652-424-954-106;;039-999-144-232-460;;005-678-092-073-451;;004-009-137-690-388;;104-238-059-591-396;;008-726-753-353-446;;021-493-537-973-647;;096-073-292-575-164;;044-714-305-100-688;;022-219-937-872-09X;;049-229-827-493-119;;002-656-962-698-37X;;071-087-832-611-753;;010-259-004-279-068;;023-595-582-283-151;;031-775-513-566-13X;;021-279-186-422-570;;073-383-664-967-409;;062-485-199-606-891;;105-395-081-326-172;;110-732-270-288-932;;041-734-312-774-137;;006-374-645-643-527;;044-134-353-590-764;;042-145-179-004-555;;003-652-868-381-630;;049-358-720-480-087;;057-988-527-188-11X;;073-711-472-325-962;;140-524-605-679-698;;039-603-244-705-17X;;007-270-294-063-175;;042-470-301-327-059;;074-543-898-223-214;;120-794-407-501-308;;001-812-494-528-980;;104-238-059-591-396;;049-922-288-675-727;;071-946-400-761-339;;050-118-521-614-073;;124-608-637-460-437;;069-732-997-606-247;;035-021-191-726-704;;033-756-731-892-872;;000-896-845-851-734;;052-054-410-331-073,pmc3618620;;10.1038/gt.2012.101;;23303281;;10.1182/blood-2013-01-306647;;pmc3701904;;23596044;;10.1038/mt.2010.265;;21139569;;pmc3034858;;10.1038/nbt.1515;;19098898;;pmc2895694;;10.1038/mt.2009.71;;pmc2835208;;19367261;;pmc3129805;;21487395;;10.1038/mt.2011.72;;24617515;;10.1089/hum.2014.011;;pmc3327605;;10.1089/hum.2011.200;;22201473;;pmc3361729;;10.1517/14712598.2012.681463;;22519910;;pmc6674861;;17108166;;10.1523/jneurosci.2795-06.2006;;24191919;;10.1089/hum.2013.021;;pmc3692458;;23825679;;10.1371/journal.pone.0067680;;10.1093/hmg/ddm289;;17913701;;10.1007/s11910-007-0024-4;;17217857;;10.1016/0022-2836(70)90057-4;;5420325;;10.1073/pnas.85.8.2444;;pmc280013;;3162770;;3118049;;10.1007/bf02603120;;10.1093/bioinformatics/5.2.151;;2720464;;10.1093/nar/12.1part1.387;;6546423;;pmc321012;;2231712;;10.1006/jmbi.1990.9999;;10.1016/s0022-2836(05)80360-2;;10.1093/nar/25.17.3389;;9254694;;pmc146917;;pmc50453;;1438297;;10.1073/pnas.89.22.10915;;10.1016/0076-6879(87)53076-2;;2828848;;10.1016/0378-1119(88)90330-7;;3243435;;10.1093/nar/16.22.10881;;pmc338945;;2849754;;8162065;;10.1038/ng0294-119;;11050953;;10.1016/s0065-3527(00)55014-3;;1644927;;pmc443142;;10.1172/jci115902;;8382374;;10.1126/science.8382374;;10.1128/jvi.61.10.3096-3101.1987;;pmc255885;;3041032;;10.1128/jvi.63.9.3822-3828.1989;;pmc250975;;2547998;;10.1128/mcb.8.10.3988;;pmc365467;;2847025;;10.1128/mcb.8.10.3988-3996.1988;;pmc2570152;;10.1128/cmr.00008-08;;18854481;;10.1038/sj.gt.3302650;;16195703;;10.1038/sj.gt.3301514;;11509958;;10.1006/mthe.2000.0219;;11124063;;pmc112967;;10516041;;10.1128/jvi.73.11.9325-9336.1999;;8661429;;10.1006/viro.1996.0367;;2153052;;10.1016/0092-8674(90)90720-y;;8396670;;pmc238031;;10.1128/jvi.67.10.6096-6104.1993;;pmc111981;;10.1128/jvi.74.10.4612-4620.2000;;10775597;;10.1016/0092-8674(83)90342-2;;6088052;;10.1517/14712590802573395;;19063698;;10.1016/s0140-6736(08)61589-5;;18940466;;18062719;;10.2165/00003495-200767180-00005;;pmc2949326;;17915569;;10.1016/j.ymthe.2004.09.017;;15585405;;10.7326/0003-4819-146-6-200703200-00007;;17371887;;12585833;;10.7326/0003-4819-138-4-200302180-00014;;pmc529421;;15578103;;10.1371/journal.pmed.0010021;;10.1073/pnas.70.7.2134;;pmc433682;;4269173;;16912578;;10.1097/01.gim.0000232477.37660.fb;;10.1093/hmg/ddm353;;18056156;;10.1016/j.neulet.2014.05.044;;24882721;;pmc6674861;;17108166;;10.1523/jneurosci.2795-06.2006;;23808551;;10.1089/hgtb.2013.076;;pmc3753728;;24191919;;10.1089/hum.2013.021;;10.1038/sj.mt.6300004;;17164772;;22149959;;pmc3265081;;10.1056/nejmoa1108046;;pmc3726158;;10.1172/jci66778;;23863627;;14964684;;10.1080/14734220310022289;;pmc3327605;;10.1089/hum.2011.200;;22201473;;10.1007/s00401-009-0619-8;;20012068;;pmc2799634;;18752295;;10.1002/jnr.21828;;19279265;;10.1523/jneurosci.4707-08.2009;;pmc2819812;;10.1038/mt.2008.171;;18682697;;10.1038/sj.gt.3301514;;11509958;;14625565;;10.1038/sj.gt.3302134;;14625564;;10.1038/sj.gt.3302133;;10.1182/blood-2005-10-4035;;pmc1895379;;16322469;;6198590;;10.1038/307273a0;;10.1038/mt.2013.266;;24419081;;pmc3918916;;24820227;;10.1007/s10545-014-9718-3;;16545619;;10.1016/j.ymthe.2006.01.006;;15235598;;10.1038/nm1076;;10.1038/mt.2013.144;;pmc3808129;;23765441,"GRAY SJNAGABHUSHAN KALBURGI SMCCOWN TJJUDE SAMULSKI R: ""Global CNS gene delivery and evasion of anti-AAV-neutralizing antibodies by intrathecal AAV administration in non-human primates"", GENE THERAPY, vol. 20, 2013, pages 450 - 459, XP055540194, DOI: 10.1038/gt.2012.101;;MINGOZZI FHIGH KA: ""Immune responses to AAV vectors: overcoming barriers to successful gene therapy"", BLOOD, vol. 122, no. 1, 4 July 2013 (2013-07-04), pages 23 - 36, XP055175008, DOI: 10.1182/blood-2013-01-306647;;ELLINWOOD NMAUSSEIL JDESMARIS NBIGOU SLIU SJENS JK ET AL.: ""Safe, efficient, and reproducible gene therapy of the brain in the dog models of Sanfilippo and Hurler syndromes"", MOL THER, vol. 19, no. 2, February 2011 (2011-02-01), pages 251 - 9, XP009150181, DOI: 10.1038/mt.2010.265;;FOUST ET AL., NAT. BIOTECHNOL., vol. 27, 2009, pages 59 - 65;;DUQUE ET AL., MOL. THER., vol. 17, 2009, pages 1187 - 1196;;GRAY ET AL., MOL. THER., vol. 19, 2011, pages 1058 - 1069;;PASSINI ET AL., HUMAN GENE THERAPY, vol. 25, 2014, pages 619 - 630;;SAMARANCH ET AL., HUM GENE THER, vol. 23, 2012, pages 382 - 389;;DAYTON RDWANG DBKLEIN RL: ""The advent of AAV9 expands applications for brain and spinal cord gene delivery"", EXPERT OPIN BIOL THER, vol. 12, no. 6, June 2012 (2012-06-01), pages 757 - 66, XP055279735, DOI: 10.1517/14712598.2012.681463;;MCCLEAN ET AL., NEUROSCI. LETT., vol. 576, 2014, pages 73 - 8;;LEVITES ET AL., J. NEUROSCI., vol. 26, pages 11923 - 8;;DIRREN ET AL., HUM. GENE THER., vol. 25, 2014, pages 109 - 20;;CHAKRABARTY PROSARIO ACRUZ PSIEMIENSKI ZCEBALLOS-DIAZ CCROSBY K ET AL.: ""Capsid serotype and timing of injection determines AAV transduction in the neonatal mice brain"", PLOS ONE, vol. 8, no. 6, 2013, pages e67680;;HAURIGOT ET AL., J. CLIN. INVEST., 1 July 2013 (2013-07-01);;SETTEMBRE ET AL., HUMAN MOL. GENET., vol. 17, 2008, pages 119 - 129;;FUKUDA ET AL., CURR. NEUROL. NEUROSCI. REP., vol. 7, 2007, pages 71 - 77;;SMITHWATERMAN, ADV. APPL. MATH., vol. 2, 1981, pages 482;;NEEDLEMANWUNSCH, J. MOL. BIOL., vol. 48, 1970, pages 443;;PEARSONLIPMAN, PROC. NAT'L. ACAD. SCI. USA, vol. 85, 1988, pages 2444;;""Current Protocols in Molecular Biology"", 1995;;FENGDOOLITTLE, J. MOL. EVOL., vol. 35, 1987, pages 351 - 360;;HIGGINSSHARP, CABIOS, vol. 5, 1989, pages 151 - 153;;DEVEREAUX ET AL., NUC. ACIDS RES., vol. 12, 1984, pages 387 - 395;;ALTSCHUL ET AL., J. MOL. BIOL., vol. 215, 1990, pages 403 - 410;;ALTSCHUL ET AL., NUCLEIC ACIDS RES., vol. 25, 1977, pages 3389 - 3402;;HENIKOFFHENIKOFF, PROC. NATL. ACAD. SCI. USA, vol. 89, 1989, pages 10915;;E. W. MARTIN: ""Remington's Pharmaceutical Sciences"", 1975, MACK PUBLISHING CO.;;BITTER ET AL., METHODS IN ENZYMOLOGY, vol. 153, 1987, pages 516 - 544;;PEARSONLIPMAN, PROC. NATL. ACAD. SCI. U.S.A., vol. 85, 1988, pages 2444;;HIGGINSSHARP, GENE, vol. 73, 1988, pages 237;;CORPET ET AL., NUCLEIC ACIDS RESEARCH, vol. 16, 1988, pages 10881;;ALTSCHUL ET AL., NATURE GENET, vol. 6, 1994, pages 119;;""Gene Therapeutics"", 1994;;HITT ET AL., ADV IN VIRUS RES, vol. 55, 2000, pages 479 - 505;;STRATFORD-PERRICAUDET ET AL., J. CLIN. INVEST., vol. 90, 1992, pages 626 - 630;;LA SALLE ET AL., SCIENCE, vol. 259, 1993, pages 988 - 990;;SAMULSKI ET AL., J. VIROL., vol. 61, 1987, pages 3096 - 3101;;SAMULSKI ET AL., J. VIROL., vol. 63, 1989, pages 3822 - 3828;;LEBKOWSKI ET AL., MOL. CELL. BIOL., vol. 8, 1988, pages 3988 - 3996;;DAYABERNS, CLIN MICROBIOL REV, vol. 21, no. 4, 2008, pages 583 - 593;;GHOSH ET AL., GENE THER, vol. 13, no. 4, 2006, pages 321 - 329;;K. FISHER ET AL., J. VIROL., vol. 70, 1993, pages 520 - 532;;MCCARTY ET AL., GENE THER., vol. 8, 2001, pages 1248 - 1254;;CHAO ET AL., MOLECULAR THERAPY, vol. 2, 2000, pages 619;;""GENBANK®"", Database accession no. NC 001540;;BRISTERMUZYCZKA, J. VIROLOGY, vol. 73, 1999, pages 9325;;MURAMATSU ET AL., VIROLOGY, vol. 221, 1996, pages 208;;SNYDER ET AL., CELL, vol. 60, 1990, pages 105;;SNYDER ET AL., J. VIROLOGY, vol. 67, 1993, pages 6096;;BRISTERMUZYCZKA, J. VIROLOGY, vol. 74, 2000, pages 4612;;SAMULSKI ET AL., CELL, vol. 33, 1983, pages 135;;CHARROW, EXPERT OPIN. BIOL. THER., vol. 9, 2009, pages 121 - 31;;ZARATEHOPKIN, LANCET, vol. 18, 2008, pages 1427 - 1435;;CLARKE, MOL. MED., vol. 10, 2008, pages e 1;;BEEK, ACTA NEUROL. BELG., vol. 106, 2006, pages 82 - 86;;ROHRBACHCLARKE, DRUGS, vol. 67, 2007, pages 2697 - 2716;;BURROW ET AL., CURR. OPIN. PEDIATR., vol. 19, 2007, pages 628 - 625;;RABEN ET AL., ACTA MYOLOGICA, vol. 26, 2007, pages 45 - 48;;RABEN ET AL., MOLECULAR THERAPY, vol. 11, 2005, pages 48 - 56;;CLARKE, ANN. INTERN MED., vol. 20, 2007, pages 425 - 433;;DESNICK, ANN. INTERN. MED., vol. 138, 2003, pages 338 - 346;;CONNOCK ET AL., HEALTH TECHNOLOGY ASSESSMENT, vol. 10, 2004, pages 136;;BEUTLER, PLOS MED., vol. 1, 2004, pages e21;;TOLARORCHARD, BIOLOGICS., vol. 2, 2008, pages 743 - 751;;TOLARORCHARD, BIOLOGIES., vol. 2, 2008, pages 743 - 751;;NEUFELD ET AL.: ""The Metabolic and Molecular Bases of Inherited Disease"", 2001, MCGRAW-HILL, pages: 3421 - 3452;;DORFMAN ET AL., PROC NATL ACAD SCI USA, vol. 43, 1957, pages 443 - 4462;;BACH ET AL., PROC. NATL. ACAD. SCI. USA., vol. 70, 1973, pages 2134 - 2213;;MUENZER ET AL., GENET. MED., vol. 8, 2006, pages 465 - 473;;TOMATSU ET AL., HUM. MOL. GENET., vol. 17, 2007, pages 815 - 824;;RESEARCH SUPPORT, NON-U.S. GOV'T, vol. 20, no. 4, April 2013 (2013-04-01), pages 450 - 9;;MCLEAN JRSMITH GAROCHA EMHAYES MABEAGAN JAHALLETT PJ ET AL.: ""Widespread neuron-specific transgene expression in brain and spinal cord following synapsin promoter-driven AAV9 neonatal intracerebroventricular injection"", NEUROSCI LETT., vol. 576, 25 July 2014 (2014-07-25), pages 73 - 8, XP028877633, DOI: 10.1016/j.neulet.2014.05.044;;LEVITES YJANSEN KSMITHSON LADAKIN RHOLLOWAY VMDAS P ET AL.: ""Intracranial adeno-associated virus-mediated delivery of anti-pan amyloid beta, amyloid beta40, and amyloid beta42 single-chain variable fragments attenuates plaque pathology in amyloid precursor protein mice"", J NEUROSCI, vol. 26, no. 46, 15 November 2006 (2006-11-15), pages 11923 - 8, XP055158899, DOI: 10.1523/JNEUROSCI.2795-06.2006;;GHOLIZADEH STHARMALINGAM SMACALDAZ MEHAMPSON DR: ""Transduction of the central nervous system after intracerebroventricular injection of adeno-associated viral vectors in neonatal and juvenile mice"", HUM GENE THER METHODS, vol. 24, no. 4, August 2013 (2013-08-01), pages 205 - 13;;DIRREN ETOWNE CLSETOLA VREDMOND DE, JR.SCHNEIDER BLAEBISCHER P: ""Intracerebroventricular injection of adeno-associated virus 6 and 9 vectors for cell type-specific transgene expression in the spinal cord"", HUM GENE THER, vol. 25, no. 2, February 2014 (2014-02-01), pages 109 - 20, XP055732373, DOI: 10.1089/hum.2013.021;;BROEKMAN MLBAEK RCCOMER LAFERNANDEZ JLSEYFRIED TNSENA-ESTEVES M: ""Complete correction of enzymatic deficiency and neurochemistry in the GM1-gangliosidosis mouse brain by neonatal adeno-associated virus-mediated gene delivery"", MOL THER, vol. 15, no. 1, January 2007 (2007-01-01), pages 30 - 7, XP009091138, DOI: 10.1038/sj.mt.6300004;;NATHWANI ACTUDDENHAM EGRANGARAJAN SROSALES CMCINTOSH JLINCH DC ET AL.: ""Adenovirus-associated virus vector-mediated gene transfer in hemophilia B"", N ENGL J MED., vol. 365, no. 25, 22 December 2011 (2011-12-22), pages 2357 - 65, XP055079598, DOI: 10.1056/NEJMoa1108046;;HAURIGOT VMARCO SRIBERA AGARCIA MRUZO AVILLACAMPA P ET AL.: ""Whole body correction of mucopolysaccharidosis IIIA by intracerebrospinal fluid gene therapy"", J CLIN INVEST, 1 July 2013 (2013-07-01);;""Bastianelli E. Distribution of calcium-binding proteins in the cerebellum"", CEREBELLUM, vol. 2, no. 4, 2003, pages 242 - 62;;SAMARANCH LSALEGIO EASAN SEBASTIAN WKELLS APFOUST KDBRINGAS JR ET AL.: ""Adeno-associated virus serotype 9 transduction in the central nervous system of nonhuman primates"", HUM GENE THER, vol. 23, no. 4, April 2012 (2012-04-01), pages 382 - 9, XP055407538, DOI: 10.1089/hum.2011.200;;SOFRONIEW MVVINTERS HV: ""Astrocytes: biology and pathology"", ACTA NEUROPATHOL, vol. 119, no. 1, January 2010 (2010-01-01), pages 7 - 35, XP019780694;;BENESOVA JHOCK MBUTENKO OPRAJEROVA IANDEROVA MCHVATAL A: ""Quantification of astrocyte volume changes during ischemia in situ reveals two populations of astrocytes in the cortex of GFAP/EGFP mice"", J NEUROSCI RES., vol. 87, no. 1, January 2009 (2009-01-01), pages 96 - 111;;OBERHEIM NATAKANO THAN XHE WLIN JHWANG F ET AL.: ""Uniquely hominid features of adult human astrocytes"", J NEUROSCI., vol. 29, no. 10, 11 March 2009 (2009-03-11), pages 3276 - 87;;MCCARTY DM: ""Self-complementary AAV vectors; advances and applications"", MOL THER., vol. 16, no. 10, October 2008 (2008-10-01), pages 1648 - 56, XP002714134, DOI: 10.1038/mt.2008.171;;MCCARTY DMMONAHAN PESAMULSKI RJ: ""Self-complementary recombinant adeno-associated virus (scAAV) vectors promote efficient transduction independently of DNA synthesis"", GENE THER., vol. 8, no. 16, August 2001 (2001-08-01), pages 1248 - 54, XP037773369, DOI: 10.1038/sj.gt.3301514;;MCCARTY DMFU HMONAHAN PETOULSON CENAIK PSAMULSKI RJ: ""Adeno-associated virus terminal repeat (TR) mutant generates self-complementary vectors to overcome the rate-limiting step to transduction in vivo"", GENE THER, vol. 10, no. 26, December 2003 (2003-12-01), pages 2112 - 8, XP002367806, DOI: 10.1038/sj.gt.3302134;;WANG ZMA HILI JSUN LZHANG JXIAO X: ""Rapid and highly efficient transduction by double-stranded adeno-associated virus vectors in vitro and in vivo"", GENE THER., vol. 10, no. 26, December 2003 (2003-12-01), pages 2105 - 11, XP055863830, DOI: 10.1038/sj.gt.3302133;;NATHWANI ACGRAY JTNG CYZHOU JSPENCE YWADDINGTON SN ET AL.: ""Self-complementary adeno-associated virus vectors containing a novel liver-specific human factor IX expression cassette enable highly efficient transduction of murine and nonhuman primate liver"", BLOOD, vol. 107, no. 7, 1 April 2006 (2006-04-01), pages 2653 - 61, XP002534783, DOI: 10.1182/blood-2005-10-4035;;FONTANA AFIERZ WWEKERLE. H: ""Astrocytes present myelin basic protein to encephalitogenic T-cell lines"", NATURE, vol. 307, no. 5948, 19 January 1984 (1984-01-19), pages 273 - 6;;SAMARANCH LSAN SEBASTIAN WKELLS APSALEGIO EAHELLER GBRINGAS JR ET AL.: ""AAV9-mediated expression of a non-self protein in nonhuman primate central nervous system triggers widespread neuroinflammation driven by antigen-presenting cell transduction"", MOL THER.;;HOLLAK CEWIJBURG FA: ""Treatment of lysosomal storage disorders: successes and challenges"", J INHERIT METAB DIS, vol. 37, no. 4, July 2014 (2014-07-01), pages 587 - 98;;SANDS MSDAVIDSON BL: ""Gene therapy for lysosomal storage diseases"", MOL THER., vol. 13, no. 5, May 2006 (2006-05-01), pages 839 - 49, XP005416300, DOI: 10.1016/j.ymthe.2006.01.006;;XIA HMAO QELIASON SLHARPER SQMARTINS IHORR HT ET AL.: ""RNAi suppresses polyglutamine-induced neurodegeneration in a model of spinocerebellar ataxia"", NAT MED, vol. 10, no. 8, August 2004 (2004-08-01), pages 816 - 20, XP002484832, DOI: 10.1038/nm1076;;COSTA MDO CLUNA-CANCALON KFISCHER SASHRAF NSOUYANG MDHARIA RM ET AL.: ""Toward RNAi therapy for the polyglutamine disease Machado-Joseph disease"", MOL THER., vol. 21, no. 10, October 2013 (2013-10-01), pages 1898 - 908, XP055590757, DOI: 10.1038/mt.2013.144",PENDING
32,WO,A1,WO 2004/091718 A1,009-298-955-028-770,2004-10-28,2004,US 2004/0010770 W,2004-04-07,US 68945503 A,2003-10-20,APPLICATION OF STIMULUS TO WHITE MATTER TO INDUCE A DESIRED PHYSIOLOGICAL RESPONSE,"The present invention relates to providing a stimulus to brain structures having high fiber density, such as white matter tracts (14, 52, 74, 87, 160, 180, 182, 204). The stimulus, which can be electrical, pharmacological and/or genetic, is operative to employ the white matters to affect associated brain structures associated with the white matter to help induce a desired physiological response, such as helping to reduce or control seizures.",CLEVELAND CLINIC FOUNDATION;;LUDERS JURGEN;;NAJM IMAD;;LUDERS HANS O;;BOULIS NICHOLAS M,LUDERS JURGEN;;NAJM IMAD;;LUDERS HANS O;;BOULIS NICHOLAS M,,https://lens.org/009-298-955-028-770,Patent Application,yes,3,6,2,8,0,A61N1/36082;;A61N1/36082;;A61N1/0529;;A61N1/0529;;A61N1/0531;;A61N1/0531;;A61N1/0534;;A61N1/0534,A61N1/05;;A61N1/18;;A61N1/36,,0,0,,,,PENDING
33,DK,T3,DK 3411484 T3,147-588-764-479-818,2023-11-20,2023,DK 17747935 T,2017-01-25,US 201662292157 P;;US 2017/0014914 W,2016-02-05,INJEKTION AF ENKELTSTRENGET ELLER SELVKOMPLEMENTÆR ADENO-ASSOCIERET VIRUS 9 I CEREBROSPINALVÆSKEN,,UNIV EMORY;;REGENXBIO INC,DONSANTE ANTHONY;;KOZARSKY KAREN;;BOULIS NICHOLAS MATTHEW;;RILEY JONATHAN PATRICK,,https://lens.org/147-588-764-479-818,Granted Patent,no,0,0,22,22,0,C12N15/86;;C12N2750/14143;;A61K48/0075;;A61P37/00;;A61P25/00;;A61K48/0075;;A61P25/00;;A61K9/0085;;C12N2750/14143;;C12N15/86;;C12N2750/14143;;C12N15/86;;A61K48/0075;;A61P37/00;;A61P25/00;;A61K9/0085;;A61K45/06,C12N15/63;;A61K48/00;;C12N15/861,,0,0,,,,ACTIVE
34,PL,T3,PL 3411484 T3,002-879-620-926-932,2024-02-19,2024,PL 17747935 T,2017-01-25,US 201662292157 P;;US 2017/0014914 W,2016-02-05,INJECTION OF SINGLE-STRANDED OR SELF-COMPLEMENTARY ADENO-ASSOCIATED VIRUS 9 INTO THE CEREBROSPINAL FLUID,,UNIV EMORY;;REGENXBIO INC,DONSANTE ANTHONY;;KOZARSKY KAREN;;BOULIS NICHOLAS MATTHEW;;RILEY JONATHAN PATRICK,,https://lens.org/002-879-620-926-932,Patent Application,no,0,0,22,22,0,C12N15/86;;C12N2750/14143;;A61K48/0075;;A61P37/00;;A61P25/00;;A61K48/0075;;A61P25/00;;A61K9/0085;;C12N2750/14143;;C12N15/86;;C12N2750/14143;;C12N15/86;;A61K48/0075;;A61P37/00;;A61P25/00;;A61K9/0085;;A61K45/06,C12N15/63;;A61K48/00;;C12N15/861,,0,0,,,,PENDING
35,SI,T1,SI 3411484 T1,004-951-555-697-032,2023-12-29,2023,SI 201731434 T,2017-01-25,US 201662292157 P;;US 2017/0014914 W;;EP 17747935 A,2016-02-05,INJECTION OF SINGLE-STRANDED OR SELF-COMPLEMENTARY ADENO-ASSOCIATED VIRUS 9 INTO THE CEREBROSPINAL FLUID,,UNIV EMORY;;REGENXBIO INC,DONSANTE ANTHONY;;KOZARSKY KAREN;;BOULIS NICHOLAS MATTHEW;;RILEY JONATHAN PATRICK,,https://lens.org/004-951-555-697-032,Granted Patent,no,0,0,22,22,0,C12N15/86;;C12N2750/14143;;A61K48/0075;;A61P37/00;;A61P25/00;;A61K48/0075;;A61P25/00;;A61K9/0085;;C12N2750/14143;;C12N15/86;;C12N2750/14143;;C12N15/86;;A61K48/0075;;A61P37/00;;A61P25/00;;A61K9/0085;;A61K45/06,C12N15/00;;A61K48/00,,0,0,,,,ACTIVE
36,FI,T3,FI 3411484 T3,116-387-277-879-771,2023-11-15,2023,FI 17747935 T,2017-01-25,US 201662292157 P;;US 2017/0014914 W,2016-02-05,INJECTION OF SINGLE-STRANDED OR SELF-COMPLEMENTARY ADENO-ASSOCIATED VIRUS 9 INTO THE CEREBROSPINAL FLUID,,UNIV EMORY;;REGENXBIO INC,DONSANTE ANTHONY;;KOZARSKY KAREN;;BOULIS NICHOLAS MATTHEW;;RILEY JONATHAN PATRICK,,https://lens.org/116-387-277-879-771,Unknown,no,0,0,22,22,0,C12N15/86;;C12N2750/14143;;A61K48/0075;;A61P37/00;;A61P25/00;;A61K48/0075;;A61P25/00;;A61K9/0085;;C12N2750/14143;;C12N15/86;;C12N2750/14143;;C12N15/86;;A61K48/0075;;A61P37/00;;A61P25/00;;A61K9/0085;;A61K45/06,C12N15/63;;A61K48/00;;C12N15/861,,0,0,,,,PENDING
37,HR,T1,HR P20231451 T1,183-740-732-739-442,2024-03-01,2024,HR P20231451 T,2017-01-25,US 201662292157 P;;EP 17747935 A;;US 2017/0014914 W,2016-02-05,INJECTION OF SINGLE-STRANDED OR SELF-COMPLEMENTARY ADENO-ASSOCIATED VIRUS 9 INTO THE CEREBROSPINAL FLUID,,UNIV EMORY;;REGENXBIO INC,DONSANTE ANTHONY;;KOZARSKY KAREN;;BOULIS NICHOLAS MATTHEW;;RILEY JONATHAN PATRICK,,https://lens.org/183-740-732-739-442,Granted Patent,no,0,0,22,22,0,C12N15/86;;C12N2750/14143;;A61K48/0075;;A61P37/00;;A61P25/00;;A61K48/0075;;A61P25/00;;A61K9/0085;;C12N2750/14143;;C12N15/86;;C12N2750/14143;;C12N15/86;;A61K48/0075;;A61P37/00;;A61P25/00;;A61K9/0085;;A61K45/06,C12N15/63;;A61K48/00;;C12N15/861,,0,0,,,,ACTIVE
38,LT,T,LT 3411484 T,133-676-899-993-533,2023-11-27,2023,LT US2017014914 T,2017-01-25,US 201662292157 P;;US 2017/0014914 W,2016-02-05,INJECTION OF SINGLE-STRANDED OR SELF-COMPLEMENTARY ADENO-ASSOCIATED VIRUS 9 INTO THE CEREBROSPINAL FLUID,,UNIV EMORY;;REGENXBIO INC,DONSANTE ANTHONY;;KOZARSKY KAREN;;BOULIS NICHOLAS MATTHEW;;RILEY JONATHAN PATRICK,,https://lens.org/133-676-899-993-533,Unknown,no,0,0,22,22,0,C12N15/86;;C12N2750/14143;;A61K48/0075;;A61P37/00;;A61P25/00;;A61K48/0075;;A61P25/00;;A61K9/0085;;C12N2750/14143;;C12N15/86;;C12N2750/14143;;C12N15/86;;A61K48/0075;;A61P37/00;;A61P25/00;;A61K9/0085;;A61K45/06,C12N15/63;;A61K48/00;;A61P25/00;;A61P37/00;;C12N15/86;;C12N15/861,,0,0,,,,PENDING
39,US,A1,US 2005/0010261 A1,170-542-899-443-417,2005-01-13,2005,US 81974904 A,2004-04-07,US 81974904 A;;US 68945503 A;;US 42007902 P;;US 46099303 P,2002-10-21,Application of stimulus to white matter to induce a desired physiological response,"The present invention relates to providing a stimulus to brain structures having high fiber density, such as white matter tracts. The stimulus, which can be electrical, pharmacological and/or genetic, is operative to employ the white matter to affect associated brain structures associated with the white matter to help induce a desired physiological response, such as helping to reduce or control seizures.",CLEVELAND CLINIC FOUNDATION,LUDERS JURGEN;;NAJM IMAD;;LUDERS HANS O;;BOULIS NICHOLAS M,CLEVELAND CLINIC FOUNDATION THE (2004-05-11),https://lens.org/170-542-899-443-417,Patent Application,yes,9,65,1,8,0,A61N1/0529;;A61N1/0534;;A61N1/36082;;A61N1/36082;;A61N1/0529;;A61N1/0534,A61N1/05;;A61N1/18;;A61N1/36,607/45,0,0,,,,DISCONTINUED
40,AU,B2,AU 2017/214283 B2,152-194-789-693-203,2023-06-29,2023,AU 2017/214283 A,2017-01-25,US 201662292157 P;;US 2017/0014914 W,2016-02-05,Injection of single-stranded or self-complementary adeno-associated virus 9 into the cerebrospinal fluid,"It is disclosed herein that ssAAV and scAAV vectors of the same serotype administered by injection into the cerebrospinal fluid (CSF) via the intracerebroventricular (ICV) or intrathecal (cisternal or lumbar) route exhibit different cellular tropisms in the central nervous system. Thus, a subject can be treated by injection into the CSF of ssAAV or scAAV vector encoding a therapeutic protein, such as an ssAAV9 or scAAV9 vector. The therapeutic protein can be targeted to specific cells using these vectors. In some embodiments, scAAV9 is utilized to achieve superior transduction in the hippocampus, cerebellum and cerebral cortex where both neurons, particularly Purkinje neurons, and glial cells (such as astrocytes) are transduced. In other embodiments, ssAAV9 is utilized to minimize transduction of astrocytes. In further embodiments, an immunosuppressive agent is also administered to the subject.",UNIV EMORY;;REGENXBIO INC,DONSANTE ANTHONY;;KOZARSKY KAREN;;BOULIS NICHOLAS MATTHEW;;RILEY JOHN PATRICK,,https://lens.org/152-194-789-693-203,Granted Patent,no,2,0,22,22,0,C12N15/86;;C12N2750/14143;;A61K48/0075;;A61P37/00;;A61P25/00;;A61K48/0075;;A61P25/00;;A61K9/0085;;C12N2750/14143;;C12N15/86;;C12N2750/14143;;C12N15/86;;A61K48/0075;;A61P37/00;;A61P25/00;;A61K9/0085;;A61K45/06,C12N15/63;;A61K48/00;;C12N15/861,,0,0,,,,ACTIVE
41,EP,B1,EP 3411484 B1,050-647-344-971-056,2023-10-04,2023,EP 17747935 A,2017-01-25,US 201662292157 P;;US 2017/0014914 W,2016-02-05,INJECTION OF SINGLE-STRANDED OR SELF-COMPLEMENTARY ADENO-ASSOCIATED VIRUS 9 INTO THE CEREBROSPINAL FLUID,,UNIV EMORY;;REGENXBIO INC,DONSANTE ANTHONY;;KOZARSKY KAREN;;BOULIS NICHOLAS MATTHEW;;RILEY JONATHAN PATRICK,REGENXBIO INC. (2023-08-16);;EMORY UNIVERSITY (2023-08-16),https://lens.org/050-647-344-971-056,Granted Patent,yes,4,0,22,22,0,C12N15/86;;C12N2750/14143;;A61K48/0075;;A61P37/00;;A61P25/00;;A61K48/0075;;A61P25/00;;A61K9/0085;;C12N2750/14143;;C12N15/86;;C12N2750/14143;;C12N15/86;;A61K48/0075;;A61P37/00;;A61P25/00;;A61K9/0085;;A61K45/06,C12N15/63;;A61K48/00;;C12N15/861,,5,0,,,"KOHEI HIRONAKA ET AL: ""Enzyme replacement in the CSF to treat metachromatic leukodystrophy in mouse model using single intracerebroventricular injection of self-complementary AAV1 vector"", SCIENTIFIC REPORTS, vol. 5, no. 1, 18 August 2015 (2015-08-18) , XP55599294, DOI: 10.1038/srep13104;;T FEDERICI ET AL: ""Robust spinal motor neuron transduction following intrathecal delivery of AAV9 in pigs"", GENE THERAPY, vol. 19, no. 8, 15 September 2011 (2011-09-15), pages 852-859, XP055279523, GB ISSN: 0969-7128, DOI: 10.1038/gt.2011.130;;LLUIS SAMARANCH ET AL: ""Strong Cortical and Spinal Cord Transduction After AAV7 and AAV9 Delivery into the Cerebrospinal Fluid of Nonhuman Primates"", HUMAN GENE THERAPY, vol. 24, no. 5, 20 March 2013 (2013-03-20) , pages 526-532, XP055540811, US ISSN: 1043-0342, DOI: 10.1089/hum.2013.005;;MEYER, K ET AL.: 'Improving Single Injection CSF Delivery of AAV9-mediated Gene Therapy for SMA: A Dose-response Study in Mice and Nonhuman Primates.' THE AMERICAN SOCIETY OF GENE & CELL THERAPY vol. 23, no. 3, 09 December 2014, pages 477 - 487, XP055337771;;'NCBI) SMN1 survival of motor neuron 1, telomeric [ Homo sapiens (human' GENE ID: 6606 30 May 2013,",ACTIVE
42,US,A1,US 2016/0074119 A1,010-182-093-754-365,2016-03-17,2016,US 201514851524 A,2015-09-11,US 201514851524 A;;US 201462049526 P,2014-09-12,DEVICES AND SYSTEMS FOR MRI-GUIDED PROCEDURES,"Devices and systems can be configured to guide an instrument to a target region. The guide system may include an imaging guide including a first segment, the first segment including a guide region and imaging coils surrounding the guide region; and a platform. The platform may include a first rail, a second rail disposed parallel to the first rail, and a positioning member disposed between the first rail and the second rail. The positioning member may include a positioning frame having an entry region. The positioning frame may be movably disposed with respect to the first and second rails in a first direction and a second direction that is perpendicular to the first direction. The platform may be disposed with respect to the imaging guide so that a position of the entry region is within the guide region.",UNIV EMORY,BOULIS NICHOLAS M;;OSHINSKI JOHN N;;LAMANNA JASON J;;ANDERSON CODY DILLION,,https://lens.org/010-182-093-754-365,Patent Application,yes,6,2,2,2,0,A61B5/055;;A61B5/4566;;A61B2017/3411;;A61B50/20;;A61B90/11;;A61B17/1707;;G01R33/285;;G01R33/285;;A61B50/20;;A61B90/11;;A61B2090/103;;A61B90/10;;G01R33/286;;A61B17/1757;;A61B17/17;;G01R33/287;;A61B50/24;;A61B17/1735;;A61B50/22,G01R33/28,,0,0,,,,ACTIVE
43,US,B2,US 10866291 B2,195-717-754-436-653,2020-12-15,2020,US 201514851524 A,2015-09-11,US 201514851524 A;;US 201462049526 P,2014-09-12,Devices and systems for MRI-guided procedures,"Devices and systems can be configured to guide an instrument to a target region. The guide system may include an imaging guide including a first segment, the first segment including a guide region and imaging coils surrounding the guide region; and a platform. The platform may include a first rail, a second rail disposed parallel to the first rail, and a positioning member disposed between the first rail and the second rail. The positioning member may include a positioning frame having an entry region. The positioning frame may be movably disposed with respect to the first and second rails in a first direction and a second direction that is perpendicular to the first direction. The platform may be disposed with respect to the imaging guide so that a position of the entry region is within the guide region.",UNIV EMORY,BOULIS NICHOLAS M;;OSHINSKI JOHN N;;LAMANNA JASON J;;ANDERSON CODY DILLION,,https://lens.org/195-717-754-436-653,Granted Patent,yes,11,0,2,2,0,A61B5/055;;A61B5/4566;;A61B2017/3411;;A61B50/20;;A61B90/11;;A61B17/1707;;G01R33/285;;G01R33/285;;A61B50/20;;A61B90/11;;A61B2090/103;;A61B90/10;;G01R33/286;;A61B17/1757;;A61B17/17;;G01R33/287;;A61B50/24;;A61B17/1735;;A61B50/22,G01R33/28;;A61B17/17;;A61B50/20;;A61B50/22;;A61B50/24;;A61B90/10;;A61B90/11,,0,0,,,,ACTIVE
44,WO,A1,WO 2020/010035 A1,193-961-951-148-214,2020-01-09,2020,US 2019/0040222 W,2019-07-02,US 201862693040 P;;US 201862731879 P;;US 201862746108 P;;US 201962823198 P,2018-07-02,CANNULA SYSTEM,"The present disclosure relates to cannula systems for delivery of a therapeutic agent to parenchymal tissue of a target subject. In certain embodiments, the cannula system is for delivery of a therapeutic agent to parenchymal tissue in the spine of a target subject. In certain embodiments, the cannula system includes a cannula positioning guide (CPG) useful in the delivery of a therapeutic agent to a localized target tissue of a subject. The guide may be used in a surgical suite or during a surgical procedure.",VOYAGER THERAPEUTICS INC,PATZKE HOLGER;;HERSCH STEVEN M;;CARROLL JENNA;;KELLS ADRIAN PHILIP;;BOULIS NICHOLAS;;WARD DONNA T,,https://lens.org/193-961-951-148-214,Patent Application,yes,38,7,2,9,8,A61M5/32;;A61M2005/3201;;A61M5/329;;A61B17/3417;;A61M5/158;;A61M5/142;;A61B2017/3405;;A61B2017/3407;;A61B2017/3411;;A61B17/3478;;A61B17/3401;;A61B90/30;;A61B17/3401;;A61B17/3421;;A61B17/3478;;A61B2017/00911;;A61B2017/00951;;A61B2017/3407;;C12N15/113;;C12N2310/14;;A61M5/158;;A61M25/0606;;A61M2210/1003,A61M5/158;;A61B17/34;;A61B90/13;;A61M5/142;;A61M5/32,,12,7,011-870-742-921-780;;014-197-836-544-586;;007-364-858-655-289;;061-728-581-199-956;;096-044-227-008-929;;045-492-027-567-784;;067-534-346-375-684,10.2144/03341dd01;;12545552;;18270879;;10.1080/17482960701791234;;10.1002/jps.2600660104;;833720;;pmc2698461;;10.1517/13543770802680195;;19441914;;10.1385/nmm:6:2-3:079;;15970625;;10.1523/jneurosci.22-16-06920.2002;;20026668;;pmc6757879;;12177190;;19259649;;10.1007/s00221-009-1742-4,"STILWELLSAMUTSKI ET AL., BIOTECHNIQUES, vol. 34, 2003, pages 148;;A. R. GENNARO: ""Remington: The Science and Practice of Pharmacy"", 2006, LIPPINCOTT WILLIAMS & WILKINS;;""Remington's Pharmaceutical Sciences"", 1985, MACK PUBLISHING COMPANY, pages: 1418;;WANG ET AL., AMYOTROPHIC LATERAL SCLER., vol. 9, no. 1, 2008, pages 50 - 58;;BERGE ET AL., JOURNAL OF PHARMACEUTICAL SCIENCE, vol. 66, 1977, pages 1 - 19;;MATHUPALA, EXPERT OPIN THER PAT., vol. 19, 2009, pages 137 - 140;;PHILIPSROTHSTEIN, EXP. NEUROL., vol. 00 14-4886, no. 14, 22 May 2014 (2014-05-22), pages 00157 - 5;;BERRY ET AL., PLOS ONE, vol. 8, no. 4, 2013;;VINCENT ET AL., NEUROMOLECULAR MEDICINE, vol. 6, 2004, pages 79 - 85;;WANG ET AL., J NEUROSCI, vol. 22, 2002, pages 6920 - 6928;;RIZVANOV AA ET AL., EXP. BRAIN RES., vol. 195, no. 1, 2009, pages 1 - 4;;TOWNE C ET AL., MOL THER., vol. 19, no. 2, 2011, pages 274 - 283",PENDING
45,US,A1,US 2021/0361318 A1,023-820-393-806-45X,2021-11-25,2021,US 201917257418 A,2019-07-02,US 201917257418 A;;US 201862693040 P;;US 201862731879 P;;US 201862746108 P;;US 201962823198 P;;US 2019/0040222 W,2018-07-02,CANNULA SYSTEM AND USE THEREOF,"The present disclosure relates to cannula systems for delivery of a therapeutic agent to parenchymal tissue of a target subject. In certain embodiments, the cannula system is for delivery of a therapeutic agent to parenchymal tissue in the spine of a target subject. In certain embodiments, the cannula system includes a cannula positioning guide (CPG) useful in the delivery of a therapeutic agent to a localized target tissue of a subject. The guide may be used in a surgical suite or during a surgical procedure.",VOYAGER THERAPEUTICS INC,PATZKE HOLGER;;HERSCH STEVEN M;;SOPER JENNA CARROLL;;KELLS ADRIAN PHILIP;;BOULIS NICHOLAS;;WARD DONNA T,VOYAGER THERAPEUTICS INC (2019-04-22);;EMORY UNIVERSITY (2019-04-22),https://lens.org/023-820-393-806-45X,Patent Application,yes,2,5,2,9,8,A61M5/32;;A61M2005/3201;;A61M5/329;;A61B17/3417;;A61M5/158;;A61M5/142;;A61B2017/3405;;A61B2017/3407;;A61B2017/3411;;A61B17/3478;;A61B17/3401;;A61B90/30;;A61B17/3401;;A61B17/3421;;A61B17/3478;;A61B2017/00911;;A61B2017/00951;;A61B2017/3407;;C12N15/113;;C12N2310/14;;A61M5/158;;A61M25/0606;;A61M2210/1003,A61B17/34;;A61B90/30;;C12N15/113,,0,0,,,,PENDING
46,WO,A1,WO 2021/222644 A1,190-274-537-462-896,2021-11-04,2021,US 2021/0029994 W,2021-04-29,US 202063017152 P,2020-04-29,"DERMAL IMPLANT DEVICES, SYSTEMS, AND METHODS OF IMPLANTING THEREOF","The disclosure relates to systems, devices and methods for a dermal implant for an external object (e.g., nipple prosthetic). A dermal implant may include a base member. The base member may include a base and a post. The post may be disposed on the base and extending perpendicular to the length of the base. The base may include a set of one or more openings. Each set of openings may form a channel within the base. The device may include an attachment member disposed on the post and configured to temporarily attach to an external object. The device may include a securing member configured to be removably disposed on the post. The device may include one or more arms configured to be disposed within each set of openings of the base.",UNIV EMORY,BOULIS NICHOLAS;;GURBANI SAUMYA;;KEIFER ORION;;BETOURNE ALEXANDRE;;CATALANO ERIC;;SUBHASH SANIKA;;BRANDVOLD ALLISON;;STEINER JUSTIN;;MULCAHY GRACE;;SINNER ELIZABETH;;ZARAGOZA NADIA,,https://lens.org/190-274-537-462-896,Patent Application,yes,5,0,1,1,0,A61F2002/526;;A61F2/78;;A61F2/12;;A61F2220/0016;;A61F2220/0041;;A61F2210/009,A61F2/52;;A44C15/00,,0,0,,,,PENDING
